Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (121-130 of 436) with videos related to

Pageof 44
Sort By:
Circulation|December 17, 2009
Inhibitors of platelet adhesionTodd L Kiefer, Richard C Becker
Current Opinion in Molecular Therapeutics|January 15, 2010
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosisRichard C Becker, Mark Y Chan
Current Interventional Cardiology Reports|August 4, 2001
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary InterventionRichard C. Becker, Frederick A. Spencer
Journal of Thrombosis and Thrombolysis|September 19, 2013
Emerging paradigms in arterial thrombosisJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 3, 2013
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinicianBenjamin A Steinberg, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 18, 2013
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular researchRobert J Mentz, Richard C Becker
Current Opinion in Pharmacology|March 4, 2016
Reversal of novel oral anticoagulantsElsayed Abo-Salem, Richard C Becker
JAMA Internal Medicine|March 22, 2023
Anticoagulation in Patients With COVID-19 Pneumonia-What Is the Optimal Intensity?Richard C Becker, Thomas L Ortel
Journal of Thrombosis and Thrombolysis|November 19, 2009
Apixaban: an emerging oral factor Xa inhibitorChristopher Roser-Jones, Richard C Becker
Journal of Thrombosis and Thrombolysis|May 13, 2009
Warfarin in vulnerable older adults with atrial fibrillationS Michael Gharacholou, Richard C Becker
Pageof 44

Showing results (121-130 of 436) with videos related to

Sort By:
Pageof 44
Circulation|December 17, 2009
Inhibitors of platelet adhesionTodd L Kiefer, Richard C Becker
Current Opinion in Molecular Therapeutics|January 15, 2010
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosisRichard C Becker, Mark Y Chan
Current Interventional Cardiology Reports|August 4, 2001
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary InterventionRichard C. Becker, Frederick A. Spencer
Journal of Thrombosis and Thrombolysis|September 19, 2013
Emerging paradigms in arterial thrombosisJames W Wisler, Richard C Becker
Journal of Thrombosis and Thrombolysis|September 3, 2013
Structure-function relationships of factor Xa inhibitors: implications for the practicing clinicianBenjamin A Steinberg, Richard C Becker
Journal of Thrombosis and Thrombolysis|July 18, 2013
Funding opportunities for clinical investigators in the early stages of career development in cardiovascular researchRobert J Mentz, Richard C Becker
Current Opinion in Pharmacology|March 4, 2016
Reversal of novel oral anticoagulantsElsayed Abo-Salem, Richard C Becker
JAMA Internal Medicine|March 22, 2023
Anticoagulation in Patients With COVID-19 Pneumonia-What Is the Optimal Intensity?Richard C Becker, Thomas L Ortel
Journal of Thrombosis and Thrombolysis|November 19, 2009
Apixaban: an emerging oral factor Xa inhibitorChristopher Roser-Jones, Richard C Becker
Journal of Thrombosis and Thrombolysis|May 13, 2009
Warfarin in vulnerable older adults with atrial fibrillationS Michael Gharacholou, Richard C Becker
Pageof 44